✦ LIBER ✦

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)

✍ Scribed by Anna Angela Di Tucci; Roberta Murru; Daniele Alberti; Bertrand Rabault; Simona Deplano; Emanuele Angelucci

Book ID: 114794172
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 461 KB
Volume: 78
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2007.00840.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

189 EFFECT OF IRON CHELATION THERAPY WIT

189 EFFECT OF IRON CHELATION THERAPY WITH DEFERASIROX (EXJADE®, ICL670) OR DEFEROXAMINE ON HEPATOCELLULAR INFLAMMATION AND LIVER FUNCTION IN PATIENTS WITH TRANSFUSIONDEPENDENT ANEMIA

✍ Y. Deugnier; B. Turlin; M. Ropert-Bouchet; B. Rabault; P. Brissot 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Normal pregnancy in a patient with β-tha

Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®)

✍ Dimitra Vini; Philippos Servos; Marouso Drosou 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

A safety, pharmacokinetic and pharmacody

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan

✍ Keisuke Miyazawa; Kazuma Ohyashiki; Akio Urabe; Tomoko Hata; Shinji Nakao; Keiya 📂 Article 📅 2008 🏛 Carden Jennings Publishing 🌐 English ⚖ 378 KB

Improved survival in red blood cell tran

Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy

✍ Heather A. Leitch; Jocelyn M. Chase; Trisha A. Goodman; Hatoon Ezzat; Meaghan D. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

## Abstract Many patients with primary myelofibrosis (PMF) become red blood cell (RBC) transfusion dependent (TD), risking iron overload (IOL). Iron chelation therapy (ICT) may decrease the risk of haemosiderosis associated organ dysfunction, though its benefit in PMF is undefined. To assess the ef

Effect of iron chelator deferasirox on c

Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome

✍ Takamasa Nishiuchi; Yuichi Okutani; Toshikazu Fujita; Kazuya Yoshida; Hiroaki Oh 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 216 KB

Safety, Tolerability, and Pharmacokineti

Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to β-Thalassemia

✍ Galanello, Renzo; Piga, Antonio; Alberti, Daniele; Rouan, Marie-Claude; Bigler, 📂 Article 📅 2003 🏛 Sage Publications 🌐 English ⚖ 122 KB